Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Improve coagulation function" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Novel low-temperature plasma operation device
ActiveCN104161584AHigh speedGood lookingSurgical instruments for heatingNarrow rangeLow temperature plasma
The invention discloses a novel low-temperature plasma operation device which comprises a high-frequency generator main machine generating two frequencies, and an operation knife handle connected with the high-frequency generator main machine and provided with an operation electrode. A generator generates the 400 k high frequency and the 1.09-mega radio frequency. The electrode is covered by a 40-50 nanometer insulating coating, a slot of 5-30 microns is manufactured on the insulating coating of a knife bit electrode with a special technology, and a conductive electrode is exposed of a narrow area at the tip end of the slot. A corresponding cutting control switch on the knife handle is operated, the high-frequency generator main machine outputs 1.09-mega radio frequency processing waveforms with corresponding energy to the electrode, the tip end of the slot of 5-30 microns of the knife bit electrode conducts radio-frequency discharge to act on water molecules in tissue to generate plasma, plasma energy is highly concentrated within a narrow range of 5-30 microns, and therefore tissue cutting is achieved. The energy is concentrated in the very small range of 5-30 microns, and heat damage cannot be caused on peripheral tissue beyond 30 microns, and therefore low-temperature cutting is achieved.
Owner:GENERAL HOSPITAL OF PLA +1
Terpenoid and preparation method and application thereof
ActiveCN103553919AAvoid smallImprove coagulation functionCarboxylic acid esters separation/purificationEster active ingredientsCoagulation functionEnzyme
The invention provides a terpenoid shown by the formula I or pharmaceutically acceptable salt, ester or hydrate thereof. The invention also provides a preparation and application of the terpenoid. In the invention, a carbon-drop diterpene new compound separated from leonurus is carbon-drop labdane diterpene obtained from the nature for the first time. The compound can obviously shorten the PT (prothrombin time), APTT (activated partial thromboplastin time) and TT (thrombin time) in vitro and obviously increase the amount of FIB (fibrinogen) in blood, and realizes a certain effect on enhancing the coagulation function, thereby providing a new option for developing a novel natural coagulation drug.
Owner:CHENGDU FIRST PHARMACEDTICAL CO LTD
High-activity blood coagulation factor XI mutant and preparation and application of gene therapy/editing vector and recombinant/fusion protein thereof
ActiveCN108220274AImprove coagulation functionGood prospects for alternative treatmentsPeptide/protein ingredientsNucleic acid vectorMutantOrganism
The invention relates to a high-activity blood coagulation factor XI mutant and preparation and application of a gene therapy / editing vector and recombinant / fusion protein thereof. A nucleotide sequence is as shown in SEQ ID NO:1-6, and an amino acid sequence is as shown in SEQ ID NO:7. The mutant provided by the invention has very high blood coagulation activity, can efficiently activate blood coagulation reaction and improve the whole blood coagulation function of the organism, is applied to therapy of hemorrhagic diseases, and has very good gene therapy, gene editing and recombinant proteinreplacement therapy prospects.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +3
Traditional Chinese medicine pill for curing amenorrhea resulted from psychotropic drugs and preparation method thereof
InactiveCN102008621AEffectively treats amenorrheaUnique formulaPill deliverySexual disorderSalvia miltiorrhizaSide effect
The invention relates to a traditional Chinese medicine pill for curing amenorrhea resulted from psychotropic drugs and a preparation method thereof. The traditional Chinese medicine pill is prepared from the following bulk drugs in parts by weight: 80-100 parts of salvia miltiorrhiza bunge, 80-100 parts of peach kernel, 80-100 parts of safflower, 30-40 parts of cinnamon, 30-40 parts of fennel, 40-60 parts of folium artemisiae argyi, 40-60 parts of rhizoma cyperi, 40-60 parts of radix linderae, 40-60 parts of angelica sinensis, 40-60 parts of szechuan lovage rhizome, 40-60 parts of twotooth achyranthes root, 40-50 parts of rhizoma corydalis, 40-60 parts of bighead atractylodes rhizome and 40-60 parts of poria. The preparation method is as follows: weighting and processing 900g of the bulk drugs in parts by weight; taking 600g of the processed bulk drugs, adding 1200ml of water in the 600g of the processed bulk drugs, decocting for 40 minutes, removing dregs, decocting once again until the decoction liquid boils, decocting by slow fire and concentrating until the volume of the decoction solution is 400ml for later use; and grinding the rest 300g of the bulk drugs into fine powder, and placing the fine powder in a pelleting container, spraying the concentrated liquid in the pelleting container to prepare into water pills, taking the water pills out of the container and drying to obtain the concentrated pills. The traditional Chinese medicine pill is a pure traditional Chinese medicine preparation, has no toxic or side effect, is convenient to take and has low price.
Owner:张月英
Medical disinfection wet tissue capable of promoting wound healing
PendingCN113116748APromote healingGrowth inhibitionAntibacterial agentsCosmetic preparationsWet wipeHistiocyte
The invention relates to the technical field of disinfection wet wipes, and discloses a medical disinfection wet wipe which is prepared by the following steps: reacting cellulose with epoxy chloropropane to obtain epoxidized cellulose, reacting the epoxidized cellulose with 1, 10-decanediol to obtain hydroxylated alkyl modified cellulose, reacting with the hydroxylated alkyl modified cellulose to obtain chloroalkylated cellulose, and further reacting the chloroalkylated cellulose with N,N-dimethyl dodecylamine to obtain obtain quaternary ammonium salt modified alkylated cellulose, dissolving the quaternary ammonium salt modified alkylated cellulose in ethanol to form an antibacterial solution, and infiltrating a non-woven fabric in the antibacterial solution to obtain the medical disinfection wet tissue capable of promoting wound healing. The cellulose can stimulate the proliferation of local tissue cells in the wound, which is conducive to wound healing. A long alkyl chain is introduced into a cellulose matrix, so that the adhesion of cellulose can be improved, the rapid hemostasis effect is achieved, quaternary ammonium salt can promote bacterial cell protein to be denatured and destroy the interiors of cells, and then growth and reproduction of bacteria are inhibited, so that the disinfection and antibacterial performance of the medical disinfection wet tissue is enhanced.
Owner:维尼健康(深圳)股份有限公司
Chitosan/ Curdlan blended membrane material and preparation method thereof
InactiveCN101948573AImprove biological activityOptimize network structureProsthesisPentaerythritolGlycerol
The invention discloses a chitosan / Curdlan blended membrane material which takes chitosan and Curdlan as base materials and takes glycerol, pentaerythritol and xylitol or sorbitol as crosslinker to be prepared by a solution blending method, wherein the feeding mass ratio of chitosan to Curdlan is 1:1 / 5-5, and the feeding quality of the crosslinker is 5-10% of total mass of the chitosan and Curdlan. The chitosan / Curdlan blended membrane material of the invention can weaken the water absorption of the pure chitosan membrane and improves the air permeability of the membrane to cause the air permeability to reach higher requirements of artificial skin.
Owner:HANGZHOU NORMAL UNIVERSITY +1
External application wound repair liquid
InactiveCN102743587AAvoid infringementReduce exudationHydroxy compound active ingredientsDermatological disorderExternal applicationFiltration
The present invention provides an external application wound repair liquid, which is characterized in that the repair liquid is prepared from sanguisorba, common bletilla tuber, japanese honeysuckle stem, and 75% ethanol. A preparation method of the external application wound repair liquid comprises: crushing the three herbs, uniformly mixing and filling into a container, adding the 75% ethanol, standing for a certain time, and carrying out repeated filtration to remove residues to obtain the external application wound repair liquid of the present invention. The external application wound repair liquid of the present invention can be used for various types of wounds, and has advantages of significant effect, simple preparation, easy use, and the like.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Application of THBS1 cytokine in preparation of medicament for treating hepatic failure
InactiveCN110448679APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemUpper gastrointestinalHepatorenal syndrome
The invention discloses application of a THBS1 cytokine in preparation of a medicament for treating hepatic failure. The temperature for transport and storage of the THBS1 cytokine-containing medicament is 2-8 DEG C, the humidity is 45-75%, and the THBS1 is a member of an ABCA superfamily and is mainly used for mediating transmembrane transport of lipids. In the application of the THBS1 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the bloodcoagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding, severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.
Owner:杭州笙源生物科技有限公司
Compound hemostasis medicine and preparation method thereof
InactiveCN101785761AImprove the immunityReduce permeabilityOrganic active ingredientsPharmaceutical non-active ingredientsIntestinal structureVitamin C
The invention provides a compound hemostasis medicine, namely a compound adrenal color hydrazone enteric capsule formulation or granular formulation, mainly containing adrenal color hydrazone, vitamin K1, vitamin C and pharmaceutic adjuvants. By using the invention, the defect lacking of blood coagulation function for the existing adrenal color hydrazone hemostasis medicine is solved to reduce blood capillary permeability and enable an injured blood capillary end to retract to realize hemostasis effect; vitamin K1 is used for affecting some blood coagulation factors and promoting or restoring blood coagulation process to speed up hemostasis; vitamin C containing synthetical collagen and histocyte is used for repairing injured blood capillary wall in time, stimulating blood coagulation function and promoting wound to heal; and the enteric formulation enables the medicine to release in intestines to effectively reduce stomach stimulation and adverse reaction of salicylic acid reaction caused by adrenal color hydrazone release in stomach. The invention also provides a method for preparing the compound adrenal color hydrazone enteric capsule formulation or granular formulation.
Owner:重庆北碚现代应用药物研究所
A New Type of Low Temperature Plasma Surgical Device
ActiveCN104161584BHigh speedGood lookingSurgical instruments for heatingEngineeringLow temperature plasma
The invention discloses a novel low-temperature plasma operation device which comprises a high-frequency generator main machine generating two frequencies, and an operation knife handle connected with the high-frequency generator main machine and provided with an operation electrode. A generator generates the 400 k high frequency and the 1.09-mega radio frequency. The electrode is covered by a 40-50 nanometer insulating coating, a slot of 5-30 microns is manufactured on the insulating coating of a knife bit electrode with a special technology, and a conductive electrode is exposed of a narrow area at the tip end of the slot. A corresponding cutting control switch on the knife handle is operated, the high-frequency generator main machine outputs 1.09-mega radio frequency processing waveforms with corresponding energy to the electrode, the tip end of the slot of 5-30 microns of the knife bit electrode conducts radio-frequency discharge to act on water molecules in tissue to generate plasma, plasma energy is highly concentrated within a narrow range of 5-30 microns, and therefore tissue cutting is achieved. The energy is concentrated in the very small range of 5-30 microns, and heat damage cannot be caused on peripheral tissue beyond 30 microns, and therefore low-temperature cutting is achieved.
Owner:GENERAL HOSPITAL OF PLA +1
Oral medicament for treating cerebral infarction and relieving limb spasm
InactiveCN102048852AReduce aggregation rateReduce damageAnthropod material medical ingredientsMuscular disorderMuscle spasmAdemetionine
The invention relates to an oral medicament for treating cerebral infarction and relieving limb spasm, and the oral medicament is prepared from the following traditional Chinese medicine active ingredients in parts by weight: 12-40 parts of membranous milkvetch root, 12-40 parts of pachyrhizua angulatus, 10-25 parts of red paeony root, 10-25 parts of szechuan lovage rhizome, 10-20 parts of peach seed, 10-25 parts of suberect spatholobus stem, 10-25 parts of common clubmoss herb, 10-25 parts of glandularstalk st.paulswort herb, 6-20 parts of twotooth achyranthes root and 3-10 parts of earthworm. Efficacy tests prove that the medicament can obviously inhibit the in-vivo blood vessel thrombosis of an animal, reduce the weight of in-vivo arterial and venous thrombus, inhibit the thrombosis and alleviate the clinical symptoms caused by the thrombus; and the medicament further has certain effect of improving coagulation function of rats, and can reduce the platelet aggregation rate, prolong the coagulation time, the PT (prothrombin time) and the APTT (activated partial thromboplastin time), have an obvious effect of improving blood rheology indicators, and can be used for significantly reducing blood viscosity of a rat blood stasis model caused by polymer dextran, improving the blood circulation, and avoiding the potential risk of the thrombosis.
Owner:马耀茹
Composite fruit juice black tea beverage and preparation method thereof
InactiveCN110338317ALower blood sugarHas a hemostatic effectPre-extraction tea treatmentFood ingredient functionsFruit juiceHigh-fructose corn syrup
The invention discloses a composite fruit juice black tea beverage and a preparation method thereof. 1 liter of the prepared composite fruit juice black tea beverage is prepared from, by weight, 1-3 gof lime juice, 3-6 g of concentrated peach juice, 5-10 g of concentrated apple juice, 1-3 g of black tea, 50-100 g of high fructose syrup, 20-50 g of glucose, 0.2-0.4 g of potassium sorbate, 0.2-0.6g of citric acid, 0.1-0.3 g of malic acid and the balance pure water. The prepared composite fruit juice black tea beverage contains not only fruit juice fragrance but also tea fragrance and is appropriately sweet, fresh, comfortable, diversified in taste and abundant in efficacy.
Owner:河南省金色康辉生物科技有限公司
Plant functional drink with heart and cerebral vessel protection function and preparation method of plant functional drink
InactiveCN107788292ALow costSweet and sour tasteMetabolism disorderNatural extract food ingredientsDiseaseDirect heating
The invention discloses a plant functional drink with a heart and cerebral vessel protection function and a preparation method of the plant functional drink. The plant functional drink is prepared from raw materials in parts by weight as follows: 10-30 parts of dried ginger slices, 10-30 parts of dried garlic slices, 5-15 parts of dried lemon slices, 2-6 parts of dried radix glycyrrhizae slices, 2-6 parts of dried hawthorn fruit slices, 1-3 parts of barley tea, 1-3 parts of dried natto, 400-800 parts of water and 100-300 parts of apple cider vinegar. Solid raw materials are dried at 90-100 DEGC for 10-20 min, the dried raw materials are mixed in proportion and crushed to form powder of 30-80 mesh, the powder is uniformly mixed with water, the obtained mixture is heated to be boiled and kept boiling for 10-30 min, cooling is conducted, an extract solution obtained after separation is mixed with the apple cider vinegar in the weight ratio of (2-4): 1, sub-packaging and sterilization areperformed, and the functional drink product is obtained. The functional drink can also be prepared by directly heating the mixed powder with the water diluted apple cider vinegar for extraction. Thecost of the raw materials is low, the processing process is simple, and the plant functional drink has good effects on prevention and adjuvant therapy of cardiovascular and cerebrovascular diseases.
Owner:上海酵宇健康管理有限公司
Application of a kind of prothrombin mutant protein and its coding nucleic acid
ActiveCN109260462BSelective procoagulant activityImprove conveniencePeptide/protein ingredientsBlood disorderMutated proteinPharmaceutical drug
The invention relates to the application of a prothrombin mutant protein and its coding nucleic acid for preparing gene therapy medicine, including linking it with a promoter and / or termination sequence and constructing an expression plasmid. The mutant protein and its encoding nucleic acid of the present invention have high blood coagulation activity, can efficiently promote blood coagulation, improve the overall blood coagulation function of the body, and have good prospects for gene therapy, gene editing and recombinant protein replacement therapy.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +3
Pharmaceutical composition containing oral anticoagulant and B vitamins and use thereof
ActiveCN104013964BLittle side effectsImprove coagulation functionOrganic active ingredientsBlood disorderVitamin b6Vitamin B12
The invention relates to a pharmaceutical composition containing a novel oral anticoagulant drug and B vitamins. One or more of the B vitamins and a pharmaceutically acceptable carrier. Among them, new oral anticoagulants mainly include dabigatran etexilate, rivaroxaban, apixaban, and edoxaban, with a content of 2.5-200mg; B vitamins mainly include folic acid compounds (preferred), vitamin B 6 , Vitamin B 12 , content is 0.1 ~ 50mg. The present invention also relates to the use of the composition in the preparation of medicines for preventing apoplexy in patients with atrial fibrillation. The medicine made from the pharmaceutical composition provided by the invention has a better effect of preventing stroke; in addition, the invention can make it convenient for patients to take medicine and increase compliance.
Owner:SHENZHEN AUSA PHARM CO LTD +2
Application of CTSG (cathepsin G) cell factor in preparation of medicaments to treat hepatic failure
InactiveCN110201149ASuppress deathInhibit apoptosisPeptide/protein ingredientsDigestive systemUpper gastrointestinalCathepsin G
The invention discloses application of a CTSG (cathepsin G) cell factor in the preparation of medicaments to treat hepatic failure. Death of mass hepatic cells occurs during the course of hepatic failure; the CTSG cell factor helps overcome the aforementioned problem. CTSG JNK (c-Jun N-terminal kinase) is one of MAPK (mitogen-activated protein kinase) family members; JNK pathway can inhibit apoptosis of hepatic cells by regulating the expression of CTSG. The CTSG cell factor can be applied to the preparation of medicaments to treat hepatic failure to significantly increase biochemical indexesof a patient, reduce bilirubin level, lower aminotransferase, improve the coagulation function, inhibit cell apoptosis, promote the regeneration of hepatic cells and bile duct cells, prevent occurrence of fatal complications, such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome, extend the survival time of the patient significantly, and increase the survival rate.
Owner:杭州笙源生物科技有限公司
Application of dll4 cytokine in preparation of medicament for treating fulminant hepatic failure
ActiveCN105267953BReduce degeneration and necrosisImprove fibrosisPeptide/protein ingredientsDigestive systemAntioxidantGene expression level
The present invention provides a use of the DLL4 cell factor in preparing a drug for treating fulminant hepatic failure. DLL4 can not only significantly improve the survival rate in a treatment of fulminant hepatic failure, but also significantly improve the survival rate by improving prognosis of a treatment of a severe or terminal stage hepatic disease having a similar underlying cause, disease progression and prognosis.
Owner:ZHEJIANG UNIV
Use of protease nexin II\KPI protein mutant
InactiveCN110051830AImprove coagulation functionPromote agglutinationPeptide/protein ingredientsPharmaceutical non-active ingredientsDiseaseMedicine
The invention relates to use of a protease nexin II\KPI protein mutant and a derivative, an analogue or a constituent fragment thereof for the preparation of a hemophilia-related disease or symptoms for the treatment of diseases or symptoms related to acquired hemophilia and hemophilia generating an inhibitor. The protease nexin II\KPI protein mutant can be applied to the preparation of medicinesfor treating hemorrhagic diseases and particularly relevant medicines for treating hemophilia having an inhibitor and has a good application prospect.
Owner:宁波百施宁生物医药科技有限公司
Application of PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of hepatic failure treatment drug
InactiveCN110279850ASuppress deathInhibit apoptosisPeptide/protein ingredientsDigestive systemAntioxidantHepatocyte apoptosis
The invention discloses an application of a PPAR (peroxisome proliferators-activated receptor) gamma cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the PPAR gamma cytokine. The problem that a large number of hepatocytes are dead in the course of hepatic failure can be solved by the PPAR gamma cytokine. PPAR gamma JNK (jun n-terminal kinase) is one of family members of MAPK, and a JNK pathway can inhibit hepatocyte apoptosis by regulating and controlling expression of PPAR gamma. Besides, damage of the liver and other organs is further aggravated due to the fact that serious liver metabolism dysfunction can appear in the hepatic failure process. PPAR gamma plays a pivotal role in lipid metabolism, and researches show that a PPAR gamma deficient type neonatal mouse has severe lipodystrophy shortly after birth.
Owner:杭州笙源生物科技有限公司
Chitosan/ Curdlan blended membrane material and preparation method thereof
InactiveCN101948573BImprove biological activityOptimize network structureProsthesisPentaerythritolGlycerol
The invention discloses a chitosan / Curdlan blended membrane material which takes chitosan and Curdlan as base materials and takes glycerol, pentaerythritol and xylitol or sorbitol as crosslinker to be prepared by a solution blending method, wherein the feeding mass ratio of chitosan to Curdlan is 1:1 / 5-5, and the feeding quality of the crosslinker is 5-10% of total mass of the chitosan and Curdlan. The chitosan / Curdlan blended membrane material of the invention can weaken the water absorption of the pure chitosan membrane and improves the air permeability of the membrane to cause the air permeability to reach higher requirements of artificial skin.
Owner:HANGZHOU NORMAL UNIVERSITY +1
Preparation and application of a highly active blood coagulation factor xi mutant and its gene therapy/editing vector, recombinant/fusion protein
ActiveCN108220274BImprove coagulation functionGood prospects for alternative treatmentsPeptide/protein ingredientsNucleic acid vectorDiseaseBlood coagulations
The present invention relates to the preparation and application of a highly active blood coagulation factor XI mutant and its gene therapy / editing vector, recombinant / fusion protein. The nucleotide sequence is such as SEQ ID NO: 1-6, and the amino acid sequence is such as SEQ ID NO: 7 shown. The invention has high blood coagulation activity, can efficiently activate blood coagulation reaction, improve the overall blood coagulation function of the body, is applied to the treatment of hemorrhagic diseases, and has good prospects for gene therapy, gene editing and recombinant protein replacement therapy.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +3
Application of AMPH (amphiphilic protein) cytokine to preparation of hepatic failure treatment drug
InactiveCN110279848ASuppress deathInhibit apoptosisPeptide/protein ingredientsDigestive systemAntioxidantHepatocyte apoptosis
The invention discloses an application of an AMPH (amphiphilic protein) cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the AMPH cytokine. On the basis of multi-center and large prospective cohort populations and samples, cross validation is executed from different angles with multiple techniques including transcriptome sequencing, multi-omics association analysis, qRT-PCR (quantitative reverse transcription-polymerase chain reaction), in-vivo validation in animal experiments and the like, and it is indicated that the AMPH cytokine can be applied to effective preparation of the hepatic failure treatment drug and the AMPH cytokine can cooperate with different solvents and stabilizers for producing drugs of different forms and dosages. Selectable administration modes in the using process comprise intravenous injection, intramuscular injection, hypodermic injection and oral administration. AMPH JNK (Jun N-terminal kinase) is one of MAPK family members, and a JNK pathway can inhibit hepatocyte apoptosis by regulating and controlling expression of AMPH.
Owner:杭州笙源生物科技有限公司
Application of VSIG4 cytokine in preparation of medicament for treating hepatic failure
InactiveCN110448680APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemUpper gastrointestinalHepatorenal syndrome
The invention discloses application of a VSIG4 cytokine in preparation of a medicament for treating hepatic failure. The dose form of the medicament is an injection or a lyophilized powder injection or a suspension, the application temperature of the VSIG4 cytokine-containing medicament is 15-30 DEG C, and the humidity is 45-75%. The VSIG4 is a member of an ABCA superfamily and is mainly used formediating transmembrane transport of lipids and regulating metabolic disorders such as hepatocyte steatosis during hepatic failure. In the application of the VSIG4 cytokine in preparation of the medicament for treating hepatic failure, the biochemical indexes of patients can be significantly improved, the bilirubin level is lowered, the transaminase is reduced, the blood coagulation function is improved, the albumin level is raised, hepatocyte death is inhibited, regeneration of hepatocytes and bile duct cells is promoted, fatal complications such as major upper gastrointestinal duct bleeding,severe hepatic encephalopathy and hepatorenal syndromes are prevented, the survival time is significantly prolonged, and the survival rate is increased.
Owner:杭州笙源生物科技有限公司
Application of IL-1R2 cell factor in preparing medicament for treating hepatic failure
InactiveCN110179970APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemSolventPopulation
The invention discloses application of an IL-1R2 cell factor in preparing medicament for treating hepatic failure. The medicament comprises pharmaceutically acceptable excipients, antioxidants and carriers of the IL-1R2 cell factor. According to the invention, based on polycentric and prospective large-cohort population and samples, multiple technological methods of transcriptome sequencing, multi-omics correlation analysis, qRT-PCR, animal experiment in vivo validation and the like are adopted, cross validation is carried out from different angles, the IL-1R2 cell factor is found to be capable of being applied to the effective preparation of the medicine for treating the hepatic failure, and can be matched with different solvents and stabilizers to produce the medicines with different dosage forms and dosages. IL-1R2 is one of the members of ABCA superfamily, and has the main functions of mediating transmembrane transport of lipid and adjusting metabolic disorders such as hepatocyte fatty degeneration in the hepatic failure process.
Owner:ZHEJIANG UNIV
Application of PRRT4 (proline rich transmembrane protein 4) cell factor in preparation of drugs to treat hepatic failure
InactiveCN110201148APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemAntioxidantUpper gastrointestinal
The invention discloses application of a PRRT4 (proline rich transmembrane protein 4) cell factor in the preparation of drugs to treat hepatic failure. The drugs include PRRT4 cell factor pharmaceutically-acceptable excipients, antioxidants and vectors. The course of hepatic failure is involved with severe metabolic disorders, especially lipidosis. PRRT4 cell factor can overcome the difficulty; PRRT4 is associated with the functionality of mesenchymal stem cells and can promote the treatment of liver healing. In the application in the preparation of drugs to treat hepatic failure, PRRT4 cell factor can evidently increase biochemical indexes of a patient, lower bilirubin level, reduce aminotransferase, improve the coagulation function, increase the albumin level, inhibit apoptosis of hepatic cells, promote the regeneration of hepatic cells and bile tube cells, prevent fatal complications, such as upper gastrointestinal bleeding, severe hepatic encephalopathy and hepatorenal syndrome, evidently extend the survival time, and increase the survival rate.
Owner:ZHEJIANG UNIV
Medicined diet for people suffering from cancer in perioperative period to eat
InactiveCN109938337AElimination of pulmonary vein thrombosisImprove coagulation functionHeavy metal active ingredientsNervous disorderMagnesiumSelenium
The invention provides a medicined diet for people suffering from cancer in the perioperative period to eat, and relates to the field of medicined diets. The diet is prepared from, by weight, 500 parts of ginseng, 500 parts of manyflower solomonseal rhizomes, 500 parts of Chinese dates, 250 parts of donkey-hide glue, 500 parts of licorice roots, 500 parts of fructus lycii, 500 parts of ginger, 500parts of arillus longan, 500 parts of common yam rhizomes, 500 parts of hawthorn fruits, 3,000 parts of whey peptide powder, 5,000 parts of soybean peptide powder, 3,000 parts of fish collagen protein peptide powder, 150 parts of oligoprocyanidins (OPC), 50 parts of vitamin E, 250 parts of vitamin C, 0.125 part of vitamin A, 0.75 part of beta carotene, 0.005 part of vitamin D, 10 parts of vitaminB1, 10 parts of vitamin B2, 7.5 parts of vitamin B3, 5 parts of vitamin B6, 0.005 part of vitamin B12, 0.2 part of folic acid, 250 parts of fish oil and extracts, 1,000 parts of inulin, 1,000 parts of fructooligosaccharide, 400 parts of calcium, 150 parts of magnesium, 10 parts of zinc, 0.05 part of selenium and 10 parts of iron. The medicined diet can eliminate pulmonary vein thrombosis, resistinfection, improve the platelet coagulation function, reduce the blood loss, reduce the postoperative adhesion, and relieve pain and mental pressure of patients.
Owner:吉林省九圣源生物科技有限公司
Application of ABCA13 cytokine to preparation of hepatic failure treatment drug
InactiveCN110279849APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemFreeze-dryingAntioxidant
The invention discloses an application of an ABCA13 cytokine to preparation of a hepatic failure treatment drug. The drug comprises a pharmaceutically acceptable excipient, antioxidant and carrier of the ABCA13 cytokine, and the drug is in the form of an injection, a freeze-dried powder injection or a suspension. ABCA13 is one of ABCA superfamily members, mediates transmembrane transport of lipids and adjusts metabolic disorders such as hepatocyte steatosis and the like in the hepatic failure process, and ABCA13 is functionally related with mesenchymal stem cells and has a treatment effect for promoting liver repair. According to the application of the ABCA13 cytokine to preparation of the hepatic failure treatment drug, biochemical indexes of a patient can be remarkably improved, bilirubin level and transaminase are reduced, coagulation function and albumin level are improved, fatal complications such as massive alimentary tract bleeding, severe hepatic encephalopathy and hepatorenal syndrome are prevented, the survival time is remarkably prolonged, and the survival rate is increased.
Owner:ZHEJIANG UNIV
Application of DEFA4 cytokine to preparation of medicaments for treating liver failure
InactiveCN110279851APromote regenerationImprove biochemical indicatorsPeptide/protein ingredientsDigestive systemCholangiocytePharmaceutical preservatives
The invention discloses application of a DEFA4 cytokine to preparation of medicaments for treating liver failure. The medicaments include pharmaceutically acceptable excipients, antioxidants and carriers of the DEFA4 cytokine. DEFA4 is one of ABCA superfamily members, severe hepatic cell necrosis and apoptosis occur during the liver failure, and bone marrow-derived mesenchymal stem cells play an important role during liver repair. In the application to the preparation of the medicaments for treating the liver failure, the DEFA4 cytokine can significantly improve biochemical indexes of a patient, reduce the bilirubin level, reduce transaminase, improve the blood coagulation function, increase the albumin level, inhibit the hepatic cell death, promote the hepatic cell and bile duct cell regeneration, and prevent occurrence of fatal complications such as upper gastrointestinal bleeding, serious hepatic encephalopathy and hepatorenal syndrome, so that the survival time is significantly prolonged and the survival rate is increased.
Owner:ZHEJIANG UNIV
Traditional Chinese medicine composition for treating and preventing diabetes lower limb vasculopathy and application thereof
ActiveCN111450177AImprove the degree of vascular disease in the lower extremitiesImprove coagulation functionMetabolism disorderCardiovascular disorderDiseaseViola yedoensis
The invention relates to a traditional Chinese medicine composition for treating and preventing diabetes lower limb vasculopathy. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight of 30-50 parts of poria cocos, 30 parts of semen plantaginis, 30-90 parts of flos lonicerae, 15 parts of radix achyranthis bidentatae and 10-30 parts ofherba violae. The invention further provides an application of the traditional Chinese medicine composition. Pharmacological and pharmacodynamic experiments prove that the traditional Chinese medicine composition can relieve the degree of lower limb vasculopathy of rats with diabetes; the blood coagulation function of rats with diabetes can be improved; and the inflammation condition of rats withdiabetes can be improved. Therefore, the compound can be used for preparing medicines for preventing and treating diseases related to diabetes lower limb vasculopathy. The extract or the compositionis simple in preparation method and low in cost, and a new medicine source is provided for preventing and treating diseases related to diabetes lower limb vasculopathy.
Owner:SHANGHAI PUTUO DISTRICT LIQUN HOSPITAL
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com